
    
      GS-9411 is being evaluated as a potential therapy to improve airway hydration and mucociliary
      clearance in patients with cystic fibrosis. This study is evaluating the safety and
      tolerability of 3 dose levels of GS-9411 as an inhaled product, compared to a matched
      placebo, administered twice daily for 14 days.
    
  